StockNews.AI
RYTM
StockNews.AI
154 days

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

1. RYTM collaborates with the Raymond A. Wood Foundation on a fatigue study. 2. The study focuses on craniopharyngioma patients and their caregivers. 3. Collaborative research aims to enhance understanding of craniopharyngioma fatigue. 4. Patient participation is encouraged for better research insights and outcomes. 5. RYTM's commitment to rare disease treatment continues with this initiative.

6m saved
Insight
Article

FAQ

Why Bullish?

Partnerships and research collaborations can enhance RYTM's market position and credibility. Previous collaborations often led to increased stock prices as they signify growth potential and commitment to innovative treatments.

How important is it?

The article highlights RYTM's proactive involvement in research, potentially increasing investor confidence and interest. The implications on patient outcomes could drive future business growth.

Why Long Term?

Long-term benefits may arise from increased patient engagement and data acquisition. Sustained research efforts can support future drug developments and market expansion.

Related Companies

MRNAVRTXNVOAMGN
New registry study to focus on impact of fatigue in people with craniopharyngioma March 18, 2025 07:00 ET  | Source: Rhythm Pharmaceuticals, Inc. BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma. “We are excited to partner with the Raymond A. Wood Foundation on this survey to learn more about fatigue and its effects related to craniopharyngiomas,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “Learning directly from patients and caregivers is important to advancing our understanding of craniopharyngiomas and fatigue and the consequences for improving care for patients.” All persons who have been diagnosed with craniopharyngioma, or their caregivers, are eligible to participate in this registry study. “We are pleased to join Rhythm in this effort to better understand craniopharyngioma survivors’ experiences with fatigue and factors that may affect it, such as weight gain and daytime sleepiness,” said Amy Wood, Founder and Executive Director of the Raymond A. Wood Foundation. To participate in the study, please visit www.rawoodfoundation.org/hptumorregistry to enroll into the Hypothalamic-Pituitary Brain Tumors Patient Registry and complete the available surveys. For those who are already enrolled in the registry, please log into your registry account: https://hptumorregistry.iamrare.org/. For questions related to the study, please contact registry@rawoodfoundation.org. About the Raymond A. Wood FoundationThe Raymond A. Wood Foundation is a parent and patient-led rare disease patient advocacy organization, dedicated to empowering survivors of craniopharyngioma and hypothalamic-pituitary brain tumors. The mission of the Raymond A. Wood Foundation is to drive research and advocate for treatment outcomes to improve quality of life for hypothalamic-pituitary brain tumor survivors. About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. The Company develops medicines for previously untreatable or undertreated diseases and provides support for healthcare providers and patients and their families. In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in rare melanocortin-4 receptor (MC4R) pathway diseases and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA. Forward-looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the relationship between craniopharyngiomas and fatigue and the potential benefits of a research collaboration with the Raymond A. Wood Foundation. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties and other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Corporate Contact:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm Pharmaceuticals, Inc.857-264-4280dconnolly@rhythmtx.com Media Contact:Sheryl SeapyReal Chemistry(949) 903-4750sseapy@realchemistry.com  

Related News